tucatinib

12 stories · following the connections

Business

Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress

By Nasdaq OMXJan 5, 2017, 1:02 PM UTC

Business

Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress

By Nasdaq OMXJan 5, 2017, 1:02 PM UTC

Business

Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress

By Nasdaq OMXJan 5, 2017, 1:02 PM UTC

Business

Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support Registration

By Nasdaq OMXDec 7, 2016, 12:00 PM UTC